The independent medical news service
05-01-2022 | Oncology | News | Article
HRQoL data reported for ENZAMET trial of enzalutamide in metastatic HSPC
The addition of enzalutamide rather than a standard nonsteroidal anti-androgen to testosterone suppression is associated with worsening of some health-related quality of life function and symptom scores in men with metastatic hormone-sensitive prostate cancer, report the ENZAMET researchers.
16-11-2021 | Oncology | News | Article
Guideline change triggers increased PSA screening
Rates of prostate-specific antigen testing have increased significantly since 2017, following the publication of guidelines reversing a previous recommendation against routine prostate cancer screening in young men, US researchers report.
Upset older man/© Willowpix / Getty Images / iStock